<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Extraction extraction-result-9982 - Theorizer</title>
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/5.15.1/css/all.min.css">
    <link rel="stylesheet" href="../style.css">
</head>
<body>
    <div class="header">
        <a href="../index.html"><i class="fas fa-flask"></i> Theorizer</a>
    </div>

    <div class="content">
        <h1>Extracted Data Details for extraction-result-9982</h1>

        <div class="section">
            <h2>Extracted Data (Header)</h2>
            <div class="info-section">
                <p><strong>Extraction ID:</strong> extraction-result-9982</p>
                <p><strong>Extraction Schema Used (ID):</strong> <a href="../schemas/extraction-schema-170.html">extraction-schema-170</a></p>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of proposed causes of Alzheimer's disease, supporting or refuting evidence for each cause, methods for detecting Alzheimer's disease (including biomarkers, imaging, cognitive tests, etc.), and the effectiveness of these detection methods (such as sensitivity, specificity, and stage of detection). Also extract any controversies, limitations, or counter-evidence related to causes or detection methods.</div>
                <p><strong>Paper ID:</strong> paper-274744373</p>
                <p><strong>Paper Title:</strong> Artificial Intelligence for Alzheimer’s Disease Detection: Enhancing Biomarker Analysis and Diagnostic Precision †</p>
                <p><strong>Paper Abstract:</strong> : Alzheimer’s disease (AD) is a progressive neurodegenerative disorder characterized by cognitive decline and memory impairment. Early and accurate detection of AD is crucial for timely intervention and effective treatment. Biomarkers such as amyloid-beta and tau proteins, genetic markers like the APOE genotype, and neuroimaging findings are essential for AD diagnosis and prognosis, but their complex interactions require advanced analytical tools. AI has emerged as a transformative tool in healthcare, offering advanced computational techniques to analyze complex biomarker data with enhanced precision. This review paper explores the advancements in diagnosing Alzheimer’s disease (AD) using artificial intelligence (AI) techniques. In the paper, we discuss the importance of diagnosing AD accurately and the potential benefits of using AI techniques for the early and accurate detection of AD. We emphasize the significance of AI in optimizing biomarker analysis for AD detection, discussing the challenges in their implementation and future implications. AI technologies can transform AD detection by significantly improving diagnostic imaging techniques, identifying key biomarkers, and standardizing the analysis of complex neuroimaging data. In this paper, we also highlight the critical role of AI in addressing challenges associated with integrating new technologies into clinical practice and providing effective solutions for consistent and reliable AD detection techniques.</p>
                <p><strong>Cost:</strong> 0.019</p>
            </div>
        </div>

        <div class="section">
            <h2>Extracted Data (Details)</h2>
            <div class="extraction-instance-container" id="e9982.0">
                <h3 class="extraction-instance">Extracted Data Instance 0 (e9982.0)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of proposed causes of Alzheimer's disease, supporting or refuting evidence for each cause, methods for detecting Alzheimer's disease (including biomarkers, imaging, cognitive tests, etc.), and the effectiveness of these detection methods (such as sensitivity, specificity, and stage of detection). Also extract any controversies, limitations, or counter-evidence related to causes or detection methods.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>Aβ accumulation</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Amyloid-beta (Aβ) accumulation / amyloid plaques</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Extracellular deposition of β-amyloid peptide in the brain forming plaques; described in the paper as an early pathological hallmark that can develop 10–20 years before cognitive symptoms.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Artificial Intelligence for Alzheimer's Disease Detection: Enhancing Biomarker Analysis and Diagnostic Precision</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>cause_type</strong></td>
                            <td>molecular / protein aggregation</td>
                        </tr>
                        <tr>
                            <td><strong>cause_description</strong></td>
                            <td>Excessive accumulation of β-amyloid peptide (notably Aβ42) forming extracellular plaques in the CNS; implicated as an early pathogenic event in AD.</td>
                        </tr>
                        <tr>
                            <td><strong>evidence_for_cause</strong></td>
                            <td>The paper cites that pathological abnormalities such as amyloid plaques occur 10–20 years prior to cognitive dysfunction and significant neuronal loss, and that amyloid deposition is visualizable by PET and reflected in lowered CSF Aβ42; multiple referenced studies and established biomarker assays (PET radiotracers, CSF Aβ assays) support the association.</td>
                        </tr>
                        <tr>
                            <td><strong>evidence_against_cause</strong></td>
                            <td>The paper does not present direct refuting experimental evidence; it frames amyloid accumulation as part of a complex interaction of pathologies and notes challenges in interpretation and implementation of biomarkers (e.g., detection decades before symptoms complicates staging and clinical decision-making).</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method_type</strong></td>
                            <td>biomarker / neuroimaging / CSF / blood-based biomarker</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method_description</strong></td>
                            <td>PET imaging of amyloid using radiotracers to visualize plaques; CSF measurement of Aβ42 (and Aβ42/Aβ40) by ELISA or mass spectrometry; emerging blood plasma assays for Aβ42/Aβ40 ratios.</td>
                        </tr>
                        <tr>
                            <td><strong>detection_performance</strong></td>
                            <td>No sensitivity/specificity values reported in this review for amyloid PET or CSF Aβ measures; paper notes amyloid pathology can be detected many years before symptoms (preclinical stage) but does not provide quantitative performance metrics in the text.</td>
                        </tr>
                        <tr>
                            <td><strong>study_type</strong></td>
                            <td>review (summarizes imaging, CSF and blood biomarker studies)</td>
                        </tr>
                        <tr>
                            <td><strong>study_population</strong></td>
                            <td>Not a single primary cohort; paper references large datasets/cohorts such as ADNI, NACC, OASIS and multiple clinical/biochemical studies (not detailed quantitatively here).</td>
                        </tr>
                        <tr>
                            <td><strong>controversies_or_limitations</strong></td>
                            <td>Detection limitations include invasiveness and cost of some methods (CSF lumbar puncture), low concentration of brain-derived Aβ in blood due to the blood–brain barrier, and difficulty interpreting amyloid positivity many years before clinical symptoms; the paper also notes broader implementation challenges and need for AI to handle complex multi-modal data.</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Artificial Intelligence for Alzheimer’s Disease Detection: Enhancing Biomarker Analysis and Diagnostic Precision †', 'publication_date_yy_mm': '2024-11'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e9982.1">
                <h3 class="extraction-instance">Extracted Data Instance 1 (e9982.1)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of proposed causes of Alzheimer's disease, supporting or refuting evidence for each cause, methods for detecting Alzheimer's disease (including biomarkers, imaging, cognitive tests, etc.), and the effectiveness of these detection methods (such as sensitivity, specificity, and stage of detection). Also extract any controversies, limitations, or counter-evidence related to causes or detection methods.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>Tau pathology</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Hyperphosphorylated tau / neurofibrillary tangles</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Intracellular aggregation of abnormal tau protein (including phosphorylated tau) forming neurofibrillary tangles and indicating neurofibrillary degeneration in AD.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Artificial Intelligence for Alzheimer's Disease Detection: Enhancing Biomarker Analysis and Diagnostic Precision</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>cause_type</strong></td>
                            <td>molecular / protein aggregation</td>
                        </tr>
                        <tr>
                            <td><strong>cause_description</strong></td>
                            <td>Abnormal tau protein (total tau and phosphorylated tau, p-tau) accumulation leading to neurofibrillary tangles and neuronal dysfunction/degeneration.</td>
                        </tr>
                        <tr>
                            <td><strong>evidence_for_cause</strong></td>
                            <td>The paper notes that CSF p-tau indicates neurofibrillary degeneration and that PET imaging can visualize tau tangles; tau is listed among core CSF biomarkers and blood-based assays under development, indicating consistent association with AD pathology across studies cited.</td>
                        </tr>
                        <tr>
                            <td><strong>evidence_against_cause</strong></td>
                            <td>No direct counter-evidence is provided in this review; the paper frames tau alongside amyloid and other processes within a multifactorial disease model.</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method_type</strong></td>
                            <td>biomarker / neuroimaging / CSF / blood-based biomarker</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method_description</strong></td>
                            <td>CSF measurement of total tau (t-tau) and phosphorylated tau (p-tau); PET imaging targeting tau pathology; emerging plasma assays for t-tau and p-tau.</td>
                        </tr>
                        <tr>
                            <td><strong>detection_performance</strong></td>
                            <td>The review does not report sensitivity/specificity values for tau assays or tau PET; it reports that these biomarkers are part of diagnostic guidelines and useful for indicating neurofibrillary degeneration, but quantitative performance metrics are not included.</td>
                        </tr>
                        <tr>
                            <td><strong>study_type</strong></td>
                            <td>review (references CSF and imaging biomarker literature)</td>
                        </tr>
                        <tr>
                            <td><strong>study_population</strong></td>
                            <td>Not specific to a single cohort within this paper; references to cohorts and analytical platforms are noted generally (e.g., ADNI, automated CSF assay studies).</td>
                        </tr>
                        <tr>
                            <td><strong>controversies_or_limitations</strong></td>
                            <td>Limitations noted include invasiveness and availability of CSF testing, low concentrations in blood complicating plasma assays, and general challenges of integrating complex biomarker data into clinical practice; the paper does not report direct challenges to tau's role but stresses multifactorial complexity.</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Artificial Intelligence for Alzheimer’s Disease Detection: Enhancing Biomarker Analysis and Diagnostic Precision †', 'publication_date_yy_mm': '2024-11'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e9982.2">
                <h3 class="extraction-instance">Extracted Data Instance 2 (e9982.2)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of proposed causes of Alzheimer's disease, supporting or refuting evidence for each cause, methods for detecting Alzheimer's disease (including biomarkers, imaging, cognitive tests, etc.), and the effectiveness of these detection methods (such as sensitivity, specificity, and stage of detection). Also extract any controversies, limitations, or counter-evidence related to causes or detection methods.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>APOE ε4</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Apolipoprotein E epsilon 4 allele (APOE ε4)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>A common genetic risk factor for late-onset AD; presence of ε4 alleles increases risk in a dose-dependent manner according to the review.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Artificial Intelligence for Alzheimer's Disease Detection: Enhancing Biomarker Analysis and Diagnostic Precision</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>cause_type</strong></td>
                            <td>genetic</td>
                        </tr>
                        <tr>
                            <td><strong>cause_description</strong></td>
                            <td>Carriage of the APOE ε4 allele (genotypes ε4/ε4 confer higher risk than ε4/ε3) is associated with increased susceptibility to AD, while ε2 alleles may be protective in some combinations.</td>
                        </tr>
                        <tr>
                            <td><strong>evidence_for_cause</strong></td>
                            <td>The paper states APOE ε4 is a key genetic biomarker with differing risks by genotype and that genetic testing (APOE genotyping) is used for risk assessment; it references integration of genetic data with omics and AI to identify early biomarkers.</td>
                        </tr>
                        <tr>
                            <td><strong>evidence_against_cause</strong></td>
                            <td>The review notes APOE genotype is informative for risk but is not used in isolation for diagnosis; the paper does not present direct contradicting genetic evidence.</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method_type</strong></td>
                            <td>genetic screening / biomarker</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method_description</strong></td>
                            <td>DNA sequencing or genotyping assays (including PCR-based methods) to determine APOE genotype.</td>
                        </tr>
                        <tr>
                            <td><strong>detection_performance</strong></td>
                            <td>No numeric sensitivity/specificity provided; paper emphasizes APOE genotyping is for risk stratification rather than definitive diagnosis.</td>
                        </tr>
                        <tr>
                            <td><strong>study_type</strong></td>
                            <td>review / synthesis of genetic biomarker literature</td>
                        </tr>
                        <tr>
                            <td><strong>study_population</strong></td>
                            <td>General population/genetic studies referenced indirectly; specific cohort details are not provided in this review text.</td>
                        </tr>
                        <tr>
                            <td><strong>controversies_or_limitations</strong></td>
                            <td>Limitations include that APOE status is predictive of risk but not diagnostic; the paper emphasizes it should not be used alone to diagnose AD and that integration with other biomarker modalities and clinical data is required.</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Artificial Intelligence for Alzheimer’s Disease Detection: Enhancing Biomarker Analysis and Diagnostic Precision †', 'publication_date_yy_mm': '2024-11'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e9982.3">
                <h3 class="extraction-instance">Extracted Data Instance 3 (e9982.3)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of proposed causes of Alzheimer's disease, supporting or refuting evidence for each cause, methods for detecting Alzheimer's disease (including biomarkers, imaging, cognitive tests, etc.), and the effectiveness of these detection methods (such as sensitivity, specificity, and stage of detection). Also extract any controversies, limitations, or counter-evidence related to causes or detection methods.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>Neuroinflammation & oxidative stress</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Neuroinflammation, altered plasticity, oxidative stress and mitochondrial dysfunction</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Reactive brain processes including chronic inflammation and oxidative/mitochondrial dysfunction are described as associated processes in AD pathogenesis and progression.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Artificial Intelligence for Alzheimer's Disease Detection: Enhancing Biomarker Analysis and Diagnostic Precision</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>cause_type</strong></td>
                            <td>molecular / inflammatory / cellular dysfunction</td>
                        </tr>
                        <tr>
                            <td><strong>cause_description</strong></td>
                            <td>Alterations in reactive processes such as neuroinflammation, changes in neuronal plasticity, oxidative stress, and mitochondrial dysfunction that accompany and likely contribute to neurodegeneration in AD.</td>
                        </tr>
                        <tr>
                            <td><strong>evidence_for_cause</strong></td>
                            <td>The paper cites these processes as associated with AD pathology and notes they are observed alongside amyloid/tau accumulation and neurodegeneration in referenced studies; they are included in the review of pathological mechanisms.</td>
                        </tr>
                        <tr>
                            <td><strong>evidence_against_cause</strong></td>
                            <td>No direct counter-evidence is provided in the review; the paper frames these processes as part of a complex, multifactorial disease mechanism.</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method_type</strong></td>
                            <td>biomarker (CSF, blood, emerging assays)</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method_description</strong></td>
                            <td>General CSF and blood biomarkers (inflammatory markers, oxidative stress indicators, mitochondrial markers) are implied as measurable but specific markers/assays are not detailed in the text.</td>
                        </tr>
                        <tr>
                            <td><strong>detection_performance</strong></td>
                            <td>Not reported in the review: no sensitivity/specificity or validated assay performance metrics for inflammatory/oxidative markers are provided here.</td>
                        </tr>
                        <tr>
                            <td><strong>study_type</strong></td>
                            <td>review / conceptual summary</td>
                        </tr>
                        <tr>
                            <td><strong>study_population</strong></td>
                            <td>Not specified within this paper (references to broader literature only).</td>
                        </tr>
                        <tr>
                            <td><strong>controversies_or_limitations</strong></td>
                            <td>The paper highlights multifactorial complexity and high-dimensional data challenges; specific inflammatory or oxidative biomarkers are not yet established or standardized for routine diagnosis in this review, and blood assays may be limited by sensitivity and blood–brain barrier effects.</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Artificial Intelligence for Alzheimer’s Disease Detection: Enhancing Biomarker Analysis and Diagnostic Precision †', 'publication_date_yy_mm': '2024-11'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e9982.4">
                <h3 class="extraction-instance">Extracted Data Instance 4 (e9982.4)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of proposed causes of Alzheimer's disease, supporting or refuting evidence for each cause, methods for detecting Alzheimer's disease (including biomarkers, imaging, cognitive tests, etc.), and the effectiveness of these detection methods (such as sensitivity, specificity, and stage of detection). Also extract any controversies, limitations, or counter-evidence related to causes or detection methods.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>Brain atrophy (MRI)</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Brain atrophy / grey matter volume loss detected by MRI</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Structural loss of brain volume (atrophy), particularly grey matter reduction, measured by MRI and associated with neurodegeneration in AD.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Artificial Intelligence for Alzheimer's Disease Detection: Enhancing Biomarker Analysis and Diagnostic Precision</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>cause_type</strong></td>
                            <td>structural neurodegeneration</td>
                        </tr>
                        <tr>
                            <td><strong>cause_description</strong></td>
                            <td>Progressive neuronal loss and structural atrophy manifesting as reduced grey matter volume on MRI; atrophy is a downstream effect of AD neurodegeneration.</td>
                        </tr>
                        <tr>
                            <td><strong>evidence_for_cause</strong></td>
                            <td>The paper lists MRI grey matter volume as a traditional biomarker reflecting structural changes in neurodegeneration and references studies that use MRI-derived features (including Popuri's MRI-based biomarker) to detect neurodegeneration and predict conversion.</td>
                        </tr>
                        <tr>
                            <td><strong>evidence_against_cause</strong></td>
                            <td>No refuting evidence presented; MRI atrophy is described as a marker of established neurodegeneration but is not specific to AD alone.</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method_type</strong></td>
                            <td>neuroimaging (MRI)</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method_description</strong></td>
                            <td>Structural MRI measuring grey matter volume and patterns of atrophy; image segmentation approaches (GMM + CNN) and machine learning classifiers (XGBoost, SVM) applied to MRI features.</td>
                        </tr>
                        <tr>
                            <td><strong>detection_performance</strong></td>
                            <td>The review reports that AI approaches applied to MRI have achieved 'high accuracy' in classification in referenced studies but does not provide consistent numerical sensitivity/specificity; one referenced model (Choi et al. on PET) had 84.2% accuracy for predicting MCI→AD conversion (PET-based), while Mehmood et al. using MRI+VGG reported high accuracy but no numeric values are given in this review.</td>
                        </tr>
                        <tr>
                            <td><strong>study_type</strong></td>
                            <td>review citing AI-driven imaging classification studies (e.g., segmentation + ML classification)</td>
                        </tr>
                        <tr>
                            <td><strong>study_population</strong></td>
                            <td>Referenced datasets include ADNI and other public neuroimaging cohorts (specific sample sizes or demographics are not enumerated in this review).</td>
                        </tr>
                        <tr>
                            <td><strong>controversies_or_limitations</strong></td>
                            <td>MRI markers reflect neurodegeneration but are not disease-specific; analyses face challenges due to noise, high dimensionality, and requirement for large labeled datasets; segmentation and standardization are nontrivial and may limit clinical translation without robust multi-site validation.</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Artificial Intelligence for Alzheimer’s Disease Detection: Enhancing Biomarker Analysis and Diagnostic Precision †', 'publication_date_yy_mm': '2024-11'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e9982.5">
                <h3 class="extraction-instance">Extracted Data Instance 5 (e9982.5)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of proposed causes of Alzheimer's disease, supporting or refuting evidence for each cause, methods for detecting Alzheimer's disease (including biomarkers, imaging, cognitive tests, etc.), and the effectiveness of these detection methods (such as sensitivity, specificity, and stage of detection). Also extract any controversies, limitations, or counter-evidence related to causes or detection methods.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>CSF core biomarkers</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Cerebrospinal fluid core biomarkers (Aβ42, total tau, phosphorylated tau)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Established CSF biomarkers used in diagnostic guidelines: decreased Aβ42 (and Aβ42/Aβ40) and increased total tau (t-tau) and phosphorylated tau (p-tau) reflect AD pathology and neuronal injury.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Artificial Intelligence for Alzheimer's Disease Detection: Enhancing Biomarker Analysis and Diagnostic Precision</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>cause_type</strong></td>
                            <td>diagnostic biomarker (molecular)</td>
                        </tr>
                        <tr>
                            <td><strong>cause_description</strong></td>
                            <td>CSF concentrations of amyloid-beta peptides (Aβ42, Aβ40), total tau, and phosphorylated tau indicating amyloid deposition and neurofibrillary degeneration respectively.</td>
                        </tr>
                        <tr>
                            <td><strong>evidence_for_cause</strong></td>
                            <td>The review states that diagnostic guidelines include CSF levels of amyloid-beta, total tau, and p-tau; it also references studies using automated platforms and unsupervised Gaussian mixture models to classify patients by CSF profiles, supporting their diagnostic utility.</td>
                        </tr>
                        <tr>
                            <td><strong>evidence_against_cause</strong></td>
                            <td>No specific refuting studies are described in the review; limitations described relate to invasiveness of lumbar puncture and variability in assays and availability.</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method_type</strong></td>
                            <td>CSF biomarker assay</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method_description</strong></td>
                            <td>Lumbar puncture to obtain CSF followed by assays (automated platforms, ELISA, mass spectrometry) measuring Aβ42 (and Aβ40), total tau, and p-tau; unsupervised ML methods (GMM) used for profiling.</td>
                        </tr>
                        <tr>
                            <td><strong>detection_performance</strong></td>
                            <td>The paper does not provide pooled sensitivity/specificity figures; it indicates these are core diagnostic markers and that automated assays combined with ML can improve biochemical profiling, but no numeric performance metrics are presented in the review.</td>
                        </tr>
                        <tr>
                            <td><strong>study_type</strong></td>
                            <td>review; references to cohort studies and automated assay comparison studies</td>
                        </tr>
                        <tr>
                            <td><strong>study_population</strong></td>
                            <td>Referenced are comparisons across large cohorts of patients with various neurological disorders (specific cohort sizes are not detailed in this review).</td>
                        </tr>
                        <tr>
                            <td><strong>controversies_or_limitations</strong></td>
                            <td>CSF testing is invasive (lumbar puncture), may be uncomfortable and carry risk; cost and availability can limit use; assay standardization and assay platform differences are challenges; the paper highlights utility but also practical barriers to broad implementation.</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Artificial Intelligence for Alzheimer’s Disease Detection: Enhancing Biomarker Analysis and Diagnostic Precision †', 'publication_date_yy_mm': '2024-11'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e9982.6">
                <h3 class="extraction-instance">Extracted Data Instance 6 (e9982.6)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of proposed causes of Alzheimer's disease, supporting or refuting evidence for each cause, methods for detecting Alzheimer's disease (including biomarkers, imaging, cognitive tests, etc.), and the effectiveness of these detection methods (such as sensitivity, specificity, and stage of detection). Also extract any controversies, limitations, or counter-evidence related to causes or detection methods.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>Blood-based biomarkers</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Plasma / blood biomarkers (Aβ42/Aβ40, t-tau, p-tau, neurofilament light chain)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Emerging noninvasive biomarkers measured in blood/plasma (amyloid peptides, tau proteins, neurofilament light chain) under active research and increasingly analyzed with AI methods to improve detection.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Artificial Intelligence for Alzheimer's Disease Detection: Enhancing Biomarker Analysis and Diagnostic Precision</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>cause_type</strong></td>
                            <td>diagnostic biomarker (molecular, peripheral)</td>
                        </tr>
                        <tr>
                            <td><strong>cause_description</strong></td>
                            <td>Brain-derived proteins (Aβ42, Aβ40, t-tau, p-tau) and neurofilament light chain (NFL) measurable in blood that reflect central pathology or neurodegeneration, though typically present at lower concentrations than in CSF.</td>
                        </tr>
                        <tr>
                            <td><strong>evidence_for_cause</strong></td>
                            <td>The review describes advances in analytical sensitivity enabling blood biomarker measurement and cites studies suggesting combining blood biomarkers with imaging improves diagnostic accuracy; it references machine learning studies selecting blood transcript sets/classifiers that separate AD from healthy controls.</td>
                        </tr>
                        <tr>
                            <td><strong>evidence_against_cause</strong></td>
                            <td>The paper emphasizes challenges: brain-derived biomarkers are at lower concentrations in blood due to the blood–brain barrier, complicating detection; no direct refuting clinical performance data are provided in the review.</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method_type</strong></td>
                            <td>blood-based biomarker assays / transcriptomics / ML</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method_description</strong></td>
                            <td>Plasma assays for Aβ42/Aβ40 and tau species, plasma NFL, and blood transcriptomics (omics) analyzed with machine learning and deep learning pipelines (including control/bias checks and visualization) to classify disease states.</td>
                        </tr>
                        <tr>
                            <td><strong>detection_performance</strong></td>
                            <td>No unified sensitivity/specificity is reported in this review; referenced studies claim promise and discriminatory ability using ML-selected blood transcript sets, but the paper does not provide aggregated numeric performance metrics.</td>
                        </tr>
                        <tr>
                            <td><strong>study_type</strong></td>
                            <td>review citing omics, ML classification, and biomarker assay studies</td>
                        </tr>
                        <tr>
                            <td><strong>study_population</strong></td>
                            <td>Studies referenced include clinical cohorts and omics datasets; specific sample sizes and demographics are not enumerated here.</td>
                        </tr>
                        <tr>
                            <td><strong>controversies_or_limitations</strong></td>
                            <td>Main limitations are low analyte concentrations in blood, analytical sensitivity requirements, potential confounding from peripheral sources, and the need to combine blood markers with imaging and clinical data for robust accuracy; validation and standardization remain necessary.</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Artificial Intelligence for Alzheimer’s Disease Detection: Enhancing Biomarker Analysis and Diagnostic Precision †', 'publication_date_yy_mm': '2024-11'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e9982.7">
                <h3 class="extraction-instance">Extracted Data Instance 7 (e9982.7)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of proposed causes of Alzheimer's disease, supporting or refuting evidence for each cause, methods for detecting Alzheimer's disease (including biomarkers, imaging, cognitive tests, etc.), and the effectiveness of these detection methods (such as sensitivity, specificity, and stage of detection). Also extract any controversies, limitations, or counter-evidence related to causes or detection methods.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>FDG-PET & metabolic imaging</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>18F-FDG PET metabolic imaging</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Fluorodeoxyglucose PET assesses brain glucose metabolism patterns; used to detect hypometabolism patterns associated with AD and has been used to train deep learning models for diagnosis.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Artificial Intelligence for Alzheimer's Disease Detection: Enhancing Biomarker Analysis and Diagnostic Precision</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>cause_type</strong></td>
                            <td>neurofunctional imaging marker (metabolic dysfunction)</td>
                        </tr>
                        <tr>
                            <td><strong>cause_description</strong></td>
                            <td>Abnormal brain glucose metabolism patterns detected by 18F-FDG PET reflect neuronal dysfunction in AD and can be used as an imaging biomarker for classification and predictive models.</td>
                        </tr>
                        <tr>
                            <td><strong>evidence_for_cause</strong></td>
                            <td>The paper cites studies where 18F-FDG PET was used to train deep CNNs (e.g., InceptionV3) and Popuri's DAT score based on FDG-PET; Choi et al.'s PET-based CNN predicted cognitive decline with reported high accuracy in referenced work.</td>
                        </tr>
                        <tr>
                            <td><strong>evidence_against_cause</strong></td>
                            <td>No direct refutation provided here; the review notes PET imaging provides functional/metabolic information complementary to amyloid/tau imaging.</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method_type</strong></td>
                            <td>neuroimaging (FDG-PET) and AI-based analysis</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method_description</strong></td>
                            <td>18F-FDG PET scanning to measure cerebral glucose metabolism followed by deep learning (CNN) analysis (InceptionV3, ensembles) to classify AD vs controls or predict progression.</td>
                        </tr>
                        <tr>
                            <td><strong>detection_performance</strong></td>
                            <td>Specific paper-reported metric: one referenced PET-based CNN (Choi et al. on predicting MCI→AD conversion using PET) achieved 84.2% accuracy; other FDG-PET deep-learning studies are described as showing strong predictive potential but numerical sensitivity/specificity are not detailed in this review.</td>
                        </tr>
                        <tr>
                            <td><strong>study_type</strong></td>
                            <td>review citing deep learning imaging studies (model development/validation on PET datasets)</td>
                        </tr>
                        <tr>
                            <td><strong>study_population</strong></td>
                            <td>Referenced usage on datasets such as ADNI and other PET cohorts; exact sample descriptions not provided in this review.</td>
                        </tr>
                        <tr>
                            <td><strong>controversies_or_limitations</strong></td>
                            <td>PET involves radionuclide exposure and cost; generalizability and robustness of deep learning models require careful validation and control for biases; the review stresses need for positive/bias controls and visualization techniques to validate deep learning findings.</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Artificial Intelligence for Alzheimer’s Disease Detection: Enhancing Biomarker Analysis and Diagnostic Precision †', 'publication_date_yy_mm': '2024-11'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e9982.8">
                <h3 class="extraction-instance">Extracted Data Instance 8 (e9982.8)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of proposed causes of Alzheimer's disease, supporting or refuting evidence for each cause, methods for detecting Alzheimer's disease (including biomarkers, imaging, cognitive tests, etc.), and the effectiveness of these detection methods (such as sensitivity, specificity, and stage of detection). Also extract any controversies, limitations, or counter-evidence related to causes or detection methods.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>AI imaging models (CNNs)</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Deep learning convolutional neural network models for AD detection (e.g., VGG, InceptionV3, ensemble CNNs)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Deep learning architectures applied to MRI and PET imaging to classify AD, distinguish AD from healthy controls, and predict MCI-to-AD conversion, often using transfer learning and ensemble strategies.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Artificial Intelligence for Alzheimer's Disease Detection: Enhancing Biomarker Analysis and Diagnostic Precision</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>cause_type</strong></td>
                            <td>detection method / computational approach</td>
                        </tr>
                        <tr>
                            <td><strong>cause_description</strong></td>
                            <td>Not a causal mechanism; computational models (CNNs, transfer learning) process imaging and biomarker data to detect patterns indicative of AD.</td>
                        </tr>
                        <tr>
                            <td><strong>evidence_for_cause</strong></td>
                            <td>The review cites multiple studies: InceptionV3 trained on F-FDG PET (prospective); Mehmood et al. applied VGG on MRI achieving 'high accuracy' for AD vs controls; Choi et al. developed a CNN predicting cognitive decline in MCI patients with 84.2% accuracy for conversion; other studies combine GMM/CNN segmentation with XGBoost/SVM classification showing promising classification performance.</td>
                        </tr>
                        <tr>
                            <td><strong>evidence_against_cause</strong></td>
                            <td>The paper notes important limitations and necessary controls: DL models require large datasets, are sensitive to noise and bias, and results need validation (including use of bias control models and visualization techniques); it references at least one study where deep learning showed no morphological abnormalities in neutrophils, indicating null findings are possible and that model outputs must be validated.</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method_type</strong></td>
                            <td>AI / machine learning / deep learning applied to imaging and biomarker data</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method_description</strong></td>
                            <td>Convolutional neural networks (InceptionV3, VGG, custom CNNs), transfer learning, ensemble models, and hybrid pipelines combining segmentation (GMM + CNN) with classifiers (XGBoost, SVM) applied to MRI, FDG-PET, amyloid PET, and blood/CSF data.</td>
                        </tr>
                        <tr>
                            <td><strong>detection_performance</strong></td>
                            <td>Reported performance in cited studies is heterogeneous; the review explicitly reports a PET-based CNN (Choi et al.) with 84.2% accuracy predicting MCI→AD conversion; other studies are described as achieving 'high accuracy' but numerical sensitivity and specificity are not consistently reported in this review.</td>
                        </tr>
                        <tr>
                            <td><strong>study_type</strong></td>
                            <td>review of AI model development and validation studies (retrospective/prospective ML studies cited)</td>
                        </tr>
                        <tr>
                            <td><strong>study_population</strong></td>
                            <td>Models are trained and validated on public neuroimaging/biomarker datasets such as ADNI, NACC, OASIS, and various clinical cohorts referenced by the cited literature; exact sizes/demographics vary by study and are not fully enumerated in this review.</td>
                        </tr>
                        <tr>
                            <td><strong>controversies_or_limitations</strong></td>
                            <td>Major limitations highlighted include high-dimensional noisy data, need for large labeled datasets, potential bias and overfitting, lack of standardized reporting of sensitivity/specificity across studies, requirement for rigorous validation (positive/bias controls), computational complexity, and challenges integrating AI tools into clinical workflows.</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Artificial Intelligence for Alzheimer’s Disease Detection: Enhancing Biomarker Analysis and Diagnostic Precision †', 'publication_date_yy_mm': '2024-11'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e9982.9">
                <h3 class="extraction-instance">Extracted Data Instance 9 (e9982.9)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of proposed causes of Alzheimer's disease, supporting or refuting evidence for each cause, methods for detecting Alzheimer's disease (including biomarkers, imaging, cognitive tests, etc.), and the effectiveness of these detection methods (such as sensitivity, specificity, and stage of detection). Also extract any controversies, limitations, or counter-evidence related to causes or detection methods.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>CSF automated assays + unsupervised ML</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Automated CSF assay platforms combined with unsupervised Gaussian mixture models</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Automated biochemical platforms for CSF core biomarkers analyzed with unsupervised machine learning (Gaussian mixture models) to classify biochemical profiles across neurological disorders.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Artificial Intelligence for Alzheimer's Disease Detection: Enhancing Biomarker Analysis and Diagnostic Precision</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>cause_type</strong></td>
                            <td>detection method / analytical pipeline</td>
                        </tr>
                        <tr>
                            <td><strong>cause_description</strong></td>
                            <td>Not a causal factor; methodological approach combining automated CSF biomarker assays (Aβ, t-tau, p-tau) with unsupervised GMM clustering to profile and classify patients biochemically.</td>
                        </tr>
                        <tr>
                            <td><strong>evidence_for_cause</strong></td>
                            <td>The paper describes a referenced study comparing two large cohorts of patients using automated assays and unsupervised GMM to classify patients by CSF biomarker profiles, suggesting improved biochemical profiling and diagnostic protocols.</td>
                        </tr>
                        <tr>
                            <td><strong>evidence_against_cause</strong></td>
                            <td>No explicit counter-evidence described in the review; practical limitations (assay availability/cost, invasiveness) remain relevant.</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method_type</strong></td>
                            <td>CSF biomarker assay + unsupervised ML</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method_description</strong></td>
                            <td>Automated CSF biomarker platforms measuring Aβ, t-tau, p-tau, with unsupervised Gaussian mixture modeling to classify patients based on biomarker distributions.</td>
                        </tr>
                        <tr>
                            <td><strong>detection_performance</strong></td>
                            <td>The review summarizes that unsupervised ML can improve biochemical profiling but does not supply numeric performance metrics (sensitivity/specificity) for the clustering/classification outcomes in the referenced study.</td>
                        </tr>
                        <tr>
                            <td><strong>study_type</strong></td>
                            <td>review citing cohort biomarker/ML study (unsupervised learning applied to CSF assays)</td>
                        </tr>
                        <tr>
                            <td><strong>study_population</strong></td>
                            <td>Two large cohorts of patients with various neurological disorders are referenced (exact sizes/demographics not specified in this review).</td>
                        </tr>
                        <tr>
                            <td><strong>controversies_or_limitations</strong></td>
                            <td>Limitations include invasiveness of CSF sampling, costs, assay variability, and the need to validate clustering-derived classes against clinical outcomes; unsupervised outputs require careful interpretation for clinical use.</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Artificial Intelligence for Alzheimer’s Disease Detection: Enhancing Biomarker Analysis and Diagnostic Precision †', 'publication_date_yy_mm': '2024-11'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
        </div>

        <div class="section">
            <h2>Potentially Relevant New Papers (mentioned by this paper)</h2>
            <ol>
                <li>A deep learning model to predict a diagnosis of Alzheimer disease by using 18F-FDG PET of the brain. <em>(Rating: 2)</em></li>
                <li>Predicting cognitive decline with deep learning of brain metabolism and amyloid imaging. <em>(Rating: 2)</em></li>
                <li>Biomarkers for the Diagnosis of Alzheimer's Disease in Clinical Practice: The Role of CSF Biomarkers during the Evolution of Diagnostic Criteria. <em>(Rating: 2)</em></li>
                <li>Biomarkers for the Early Detection and Progression of Alzheimer's Disease. <em>(Rating: 2)</em></li>
                <li>A Survey of Deep Learning for Alzheimer's Disease. <em>(Rating: 1)</em></li>
                <li>Machine Learning Driven Profiling of Cerebrospinal Fluid Core Biomarkers in Alzheimer's Disease and Other Neurological Disorders. <em>(Rating: 2)</em></li>
                <li>Blood Transcript Biomarkers Selected by Machine Learning Algorithm Classify Neurodegenerative Diseases including Alzheimer's Disease. <em>(Rating: 2)</em></li>
                <li>Advancements in computer-assisted diagnosis of Alzheimer's disease: A comprehensive survey of neuroimaging methods and AI techniques for early detection. <em>(Rating: 1)</em></li>
            </ol>
        </div>

        <div class="section">
            <h2>Extracted Data (Debug)</h2>
            <pre><code>{
    "id": "extraction-result-9982",
    "paper_id": "paper-274744373",
    "extraction_schema_id": "extraction-schema-170",
    "extracted_data": [
        {
            "name_short": "Aβ accumulation",
            "name_full": "Amyloid-beta (Aβ) accumulation / amyloid plaques",
            "brief_description": "Extracellular deposition of β-amyloid peptide in the brain forming plaques; described in the paper as an early pathological hallmark that can develop 10–20 years before cognitive symptoms.",
            "citation_title": "Artificial Intelligence for Alzheimer's Disease Detection: Enhancing Biomarker Analysis and Diagnostic Precision",
            "mention_or_use": "mention",
            "cause_type": "molecular / protein aggregation",
            "cause_description": "Excessive accumulation of β-amyloid peptide (notably Aβ42) forming extracellular plaques in the CNS; implicated as an early pathogenic event in AD.",
            "evidence_for_cause": "The paper cites that pathological abnormalities such as amyloid plaques occur 10–20 years prior to cognitive dysfunction and significant neuronal loss, and that amyloid deposition is visualizable by PET and reflected in lowered CSF Aβ42; multiple referenced studies and established biomarker assays (PET radiotracers, CSF Aβ assays) support the association.",
            "evidence_against_cause": "The paper does not present direct refuting experimental evidence; it frames amyloid accumulation as part of a complex interaction of pathologies and notes challenges in interpretation and implementation of biomarkers (e.g., detection decades before symptoms complicates staging and clinical decision-making).",
            "detection_method_type": "biomarker / neuroimaging / CSF / blood-based biomarker",
            "detection_method_description": "PET imaging of amyloid using radiotracers to visualize plaques; CSF measurement of Aβ42 (and Aβ42/Aβ40) by ELISA or mass spectrometry; emerging blood plasma assays for Aβ42/Aβ40 ratios.",
            "detection_performance": "No sensitivity/specificity values reported in this review for amyloid PET or CSF Aβ measures; paper notes amyloid pathology can be detected many years before symptoms (preclinical stage) but does not provide quantitative performance metrics in the text.",
            "study_type": "review (summarizes imaging, CSF and blood biomarker studies)",
            "study_population": "Not a single primary cohort; paper references large datasets/cohorts such as ADNI, NACC, OASIS and multiple clinical/biochemical studies (not detailed quantitatively here).",
            "controversies_or_limitations": "Detection limitations include invasiveness and cost of some methods (CSF lumbar puncture), low concentration of brain-derived Aβ in blood due to the blood–brain barrier, and difficulty interpreting amyloid positivity many years before clinical symptoms; the paper also notes broader implementation challenges and need for AI to handle complex multi-modal data.",
            "uuid": "e9982.0",
            "source_info": {
                "paper_title": "Artificial Intelligence for Alzheimer’s Disease Detection: Enhancing Biomarker Analysis and Diagnostic Precision †",
                "publication_date_yy_mm": "2024-11"
            }
        },
        {
            "name_short": "Tau pathology",
            "name_full": "Hyperphosphorylated tau / neurofibrillary tangles",
            "brief_description": "Intracellular aggregation of abnormal tau protein (including phosphorylated tau) forming neurofibrillary tangles and indicating neurofibrillary degeneration in AD.",
            "citation_title": "Artificial Intelligence for Alzheimer's Disease Detection: Enhancing Biomarker Analysis and Diagnostic Precision",
            "mention_or_use": "mention",
            "cause_type": "molecular / protein aggregation",
            "cause_description": "Abnormal tau protein (total tau and phosphorylated tau, p-tau) accumulation leading to neurofibrillary tangles and neuronal dysfunction/degeneration.",
            "evidence_for_cause": "The paper notes that CSF p-tau indicates neurofibrillary degeneration and that PET imaging can visualize tau tangles; tau is listed among core CSF biomarkers and blood-based assays under development, indicating consistent association with AD pathology across studies cited.",
            "evidence_against_cause": "No direct counter-evidence is provided in this review; the paper frames tau alongside amyloid and other processes within a multifactorial disease model.",
            "detection_method_type": "biomarker / neuroimaging / CSF / blood-based biomarker",
            "detection_method_description": "CSF measurement of total tau (t-tau) and phosphorylated tau (p-tau); PET imaging targeting tau pathology; emerging plasma assays for t-tau and p-tau.",
            "detection_performance": "The review does not report sensitivity/specificity values for tau assays or tau PET; it reports that these biomarkers are part of diagnostic guidelines and useful for indicating neurofibrillary degeneration, but quantitative performance metrics are not included.",
            "study_type": "review (references CSF and imaging biomarker literature)",
            "study_population": "Not specific to a single cohort within this paper; references to cohorts and analytical platforms are noted generally (e.g., ADNI, automated CSF assay studies).",
            "controversies_or_limitations": "Limitations noted include invasiveness and availability of CSF testing, low concentrations in blood complicating plasma assays, and general challenges of integrating complex biomarker data into clinical practice; the paper does not report direct challenges to tau's role but stresses multifactorial complexity.",
            "uuid": "e9982.1",
            "source_info": {
                "paper_title": "Artificial Intelligence for Alzheimer’s Disease Detection: Enhancing Biomarker Analysis and Diagnostic Precision †",
                "publication_date_yy_mm": "2024-11"
            }
        },
        {
            "name_short": "APOE ε4",
            "name_full": "Apolipoprotein E epsilon 4 allele (APOE ε4)",
            "brief_description": "A common genetic risk factor for late-onset AD; presence of ε4 alleles increases risk in a dose-dependent manner according to the review.",
            "citation_title": "Artificial Intelligence for Alzheimer's Disease Detection: Enhancing Biomarker Analysis and Diagnostic Precision",
            "mention_or_use": "mention",
            "cause_type": "genetic",
            "cause_description": "Carriage of the APOE ε4 allele (genotypes ε4/ε4 confer higher risk than ε4/ε3) is associated with increased susceptibility to AD, while ε2 alleles may be protective in some combinations.",
            "evidence_for_cause": "The paper states APOE ε4 is a key genetic biomarker with differing risks by genotype and that genetic testing (APOE genotyping) is used for risk assessment; it references integration of genetic data with omics and AI to identify early biomarkers.",
            "evidence_against_cause": "The review notes APOE genotype is informative for risk but is not used in isolation for diagnosis; the paper does not present direct contradicting genetic evidence.",
            "detection_method_type": "genetic screening / biomarker",
            "detection_method_description": "DNA sequencing or genotyping assays (including PCR-based methods) to determine APOE genotype.",
            "detection_performance": "No numeric sensitivity/specificity provided; paper emphasizes APOE genotyping is for risk stratification rather than definitive diagnosis.",
            "study_type": "review / synthesis of genetic biomarker literature",
            "study_population": "General population/genetic studies referenced indirectly; specific cohort details are not provided in this review text.",
            "controversies_or_limitations": "Limitations include that APOE status is predictive of risk but not diagnostic; the paper emphasizes it should not be used alone to diagnose AD and that integration with other biomarker modalities and clinical data is required.",
            "uuid": "e9982.2",
            "source_info": {
                "paper_title": "Artificial Intelligence for Alzheimer’s Disease Detection: Enhancing Biomarker Analysis and Diagnostic Precision †",
                "publication_date_yy_mm": "2024-11"
            }
        },
        {
            "name_short": "Neuroinflammation & oxidative stress",
            "name_full": "Neuroinflammation, altered plasticity, oxidative stress and mitochondrial dysfunction",
            "brief_description": "Reactive brain processes including chronic inflammation and oxidative/mitochondrial dysfunction are described as associated processes in AD pathogenesis and progression.",
            "citation_title": "Artificial Intelligence for Alzheimer's Disease Detection: Enhancing Biomarker Analysis and Diagnostic Precision",
            "mention_or_use": "mention",
            "cause_type": "molecular / inflammatory / cellular dysfunction",
            "cause_description": "Alterations in reactive processes such as neuroinflammation, changes in neuronal plasticity, oxidative stress, and mitochondrial dysfunction that accompany and likely contribute to neurodegeneration in AD.",
            "evidence_for_cause": "The paper cites these processes as associated with AD pathology and notes they are observed alongside amyloid/tau accumulation and neurodegeneration in referenced studies; they are included in the review of pathological mechanisms.",
            "evidence_against_cause": "No direct counter-evidence is provided in the review; the paper frames these processes as part of a complex, multifactorial disease mechanism.",
            "detection_method_type": "biomarker (CSF, blood, emerging assays)",
            "detection_method_description": "General CSF and blood biomarkers (inflammatory markers, oxidative stress indicators, mitochondrial markers) are implied as measurable but specific markers/assays are not detailed in the text.",
            "detection_performance": "Not reported in the review: no sensitivity/specificity or validated assay performance metrics for inflammatory/oxidative markers are provided here.",
            "study_type": "review / conceptual summary",
            "study_population": "Not specified within this paper (references to broader literature only).",
            "controversies_or_limitations": "The paper highlights multifactorial complexity and high-dimensional data challenges; specific inflammatory or oxidative biomarkers are not yet established or standardized for routine diagnosis in this review, and blood assays may be limited by sensitivity and blood–brain barrier effects.",
            "uuid": "e9982.3",
            "source_info": {
                "paper_title": "Artificial Intelligence for Alzheimer’s Disease Detection: Enhancing Biomarker Analysis and Diagnostic Precision †",
                "publication_date_yy_mm": "2024-11"
            }
        },
        {
            "name_short": "Brain atrophy (MRI)",
            "name_full": "Brain atrophy / grey matter volume loss detected by MRI",
            "brief_description": "Structural loss of brain volume (atrophy), particularly grey matter reduction, measured by MRI and associated with neurodegeneration in AD.",
            "citation_title": "Artificial Intelligence for Alzheimer's Disease Detection: Enhancing Biomarker Analysis and Diagnostic Precision",
            "mention_or_use": "mention",
            "cause_type": "structural neurodegeneration",
            "cause_description": "Progressive neuronal loss and structural atrophy manifesting as reduced grey matter volume on MRI; atrophy is a downstream effect of AD neurodegeneration.",
            "evidence_for_cause": "The paper lists MRI grey matter volume as a traditional biomarker reflecting structural changes in neurodegeneration and references studies that use MRI-derived features (including Popuri's MRI-based biomarker) to detect neurodegeneration and predict conversion.",
            "evidence_against_cause": "No refuting evidence presented; MRI atrophy is described as a marker of established neurodegeneration but is not specific to AD alone.",
            "detection_method_type": "neuroimaging (MRI)",
            "detection_method_description": "Structural MRI measuring grey matter volume and patterns of atrophy; image segmentation approaches (GMM + CNN) and machine learning classifiers (XGBoost, SVM) applied to MRI features.",
            "detection_performance": "The review reports that AI approaches applied to MRI have achieved 'high accuracy' in classification in referenced studies but does not provide consistent numerical sensitivity/specificity; one referenced model (Choi et al. on PET) had 84.2% accuracy for predicting MCI→AD conversion (PET-based), while Mehmood et al. using MRI+VGG reported high accuracy but no numeric values are given in this review.",
            "study_type": "review citing AI-driven imaging classification studies (e.g., segmentation + ML classification)",
            "study_population": "Referenced datasets include ADNI and other public neuroimaging cohorts (specific sample sizes or demographics are not enumerated in this review).",
            "controversies_or_limitations": "MRI markers reflect neurodegeneration but are not disease-specific; analyses face challenges due to noise, high dimensionality, and requirement for large labeled datasets; segmentation and standardization are nontrivial and may limit clinical translation without robust multi-site validation.",
            "uuid": "e9982.4",
            "source_info": {
                "paper_title": "Artificial Intelligence for Alzheimer’s Disease Detection: Enhancing Biomarker Analysis and Diagnostic Precision †",
                "publication_date_yy_mm": "2024-11"
            }
        },
        {
            "name_short": "CSF core biomarkers",
            "name_full": "Cerebrospinal fluid core biomarkers (Aβ42, total tau, phosphorylated tau)",
            "brief_description": "Established CSF biomarkers used in diagnostic guidelines: decreased Aβ42 (and Aβ42/Aβ40) and increased total tau (t-tau) and phosphorylated tau (p-tau) reflect AD pathology and neuronal injury.",
            "citation_title": "Artificial Intelligence for Alzheimer's Disease Detection: Enhancing Biomarker Analysis and Diagnostic Precision",
            "mention_or_use": "mention",
            "cause_type": "diagnostic biomarker (molecular)",
            "cause_description": "CSF concentrations of amyloid-beta peptides (Aβ42, Aβ40), total tau, and phosphorylated tau indicating amyloid deposition and neurofibrillary degeneration respectively.",
            "evidence_for_cause": "The review states that diagnostic guidelines include CSF levels of amyloid-beta, total tau, and p-tau; it also references studies using automated platforms and unsupervised Gaussian mixture models to classify patients by CSF profiles, supporting their diagnostic utility.",
            "evidence_against_cause": "No specific refuting studies are described in the review; limitations described relate to invasiveness of lumbar puncture and variability in assays and availability.",
            "detection_method_type": "CSF biomarker assay",
            "detection_method_description": "Lumbar puncture to obtain CSF followed by assays (automated platforms, ELISA, mass spectrometry) measuring Aβ42 (and Aβ40), total tau, and p-tau; unsupervised ML methods (GMM) used for profiling.",
            "detection_performance": "The paper does not provide pooled sensitivity/specificity figures; it indicates these are core diagnostic markers and that automated assays combined with ML can improve biochemical profiling, but no numeric performance metrics are presented in the review.",
            "study_type": "review; references to cohort studies and automated assay comparison studies",
            "study_population": "Referenced are comparisons across large cohorts of patients with various neurological disorders (specific cohort sizes are not detailed in this review).",
            "controversies_or_limitations": "CSF testing is invasive (lumbar puncture), may be uncomfortable and carry risk; cost and availability can limit use; assay standardization and assay platform differences are challenges; the paper highlights utility but also practical barriers to broad implementation.",
            "uuid": "e9982.5",
            "source_info": {
                "paper_title": "Artificial Intelligence for Alzheimer’s Disease Detection: Enhancing Biomarker Analysis and Diagnostic Precision †",
                "publication_date_yy_mm": "2024-11"
            }
        },
        {
            "name_short": "Blood-based biomarkers",
            "name_full": "Plasma / blood biomarkers (Aβ42/Aβ40, t-tau, p-tau, neurofilament light chain)",
            "brief_description": "Emerging noninvasive biomarkers measured in blood/plasma (amyloid peptides, tau proteins, neurofilament light chain) under active research and increasingly analyzed with AI methods to improve detection.",
            "citation_title": "Artificial Intelligence for Alzheimer's Disease Detection: Enhancing Biomarker Analysis and Diagnostic Precision",
            "mention_or_use": "mention",
            "cause_type": "diagnostic biomarker (molecular, peripheral)",
            "cause_description": "Brain-derived proteins (Aβ42, Aβ40, t-tau, p-tau) and neurofilament light chain (NFL) measurable in blood that reflect central pathology or neurodegeneration, though typically present at lower concentrations than in CSF.",
            "evidence_for_cause": "The review describes advances in analytical sensitivity enabling blood biomarker measurement and cites studies suggesting combining blood biomarkers with imaging improves diagnostic accuracy; it references machine learning studies selecting blood transcript sets/classifiers that separate AD from healthy controls.",
            "evidence_against_cause": "The paper emphasizes challenges: brain-derived biomarkers are at lower concentrations in blood due to the blood–brain barrier, complicating detection; no direct refuting clinical performance data are provided in the review.",
            "detection_method_type": "blood-based biomarker assays / transcriptomics / ML",
            "detection_method_description": "Plasma assays for Aβ42/Aβ40 and tau species, plasma NFL, and blood transcriptomics (omics) analyzed with machine learning and deep learning pipelines (including control/bias checks and visualization) to classify disease states.",
            "detection_performance": "No unified sensitivity/specificity is reported in this review; referenced studies claim promise and discriminatory ability using ML-selected blood transcript sets, but the paper does not provide aggregated numeric performance metrics.",
            "study_type": "review citing omics, ML classification, and biomarker assay studies",
            "study_population": "Studies referenced include clinical cohorts and omics datasets; specific sample sizes and demographics are not enumerated here.",
            "controversies_or_limitations": "Main limitations are low analyte concentrations in blood, analytical sensitivity requirements, potential confounding from peripheral sources, and the need to combine blood markers with imaging and clinical data for robust accuracy; validation and standardization remain necessary.",
            "uuid": "e9982.6",
            "source_info": {
                "paper_title": "Artificial Intelligence for Alzheimer’s Disease Detection: Enhancing Biomarker Analysis and Diagnostic Precision †",
                "publication_date_yy_mm": "2024-11"
            }
        },
        {
            "name_short": "FDG-PET & metabolic imaging",
            "name_full": "18F-FDG PET metabolic imaging",
            "brief_description": "Fluorodeoxyglucose PET assesses brain glucose metabolism patterns; used to detect hypometabolism patterns associated with AD and has been used to train deep learning models for diagnosis.",
            "citation_title": "Artificial Intelligence for Alzheimer's Disease Detection: Enhancing Biomarker Analysis and Diagnostic Precision",
            "mention_or_use": "mention",
            "cause_type": "neurofunctional imaging marker (metabolic dysfunction)",
            "cause_description": "Abnormal brain glucose metabolism patterns detected by 18F-FDG PET reflect neuronal dysfunction in AD and can be used as an imaging biomarker for classification and predictive models.",
            "evidence_for_cause": "The paper cites studies where 18F-FDG PET was used to train deep CNNs (e.g., InceptionV3) and Popuri's DAT score based on FDG-PET; Choi et al.'s PET-based CNN predicted cognitive decline with reported high accuracy in referenced work.",
            "evidence_against_cause": "No direct refutation provided here; the review notes PET imaging provides functional/metabolic information complementary to amyloid/tau imaging.",
            "detection_method_type": "neuroimaging (FDG-PET) and AI-based analysis",
            "detection_method_description": "18F-FDG PET scanning to measure cerebral glucose metabolism followed by deep learning (CNN) analysis (InceptionV3, ensembles) to classify AD vs controls or predict progression.",
            "detection_performance": "Specific paper-reported metric: one referenced PET-based CNN (Choi et al. on predicting MCI→AD conversion using PET) achieved 84.2% accuracy; other FDG-PET deep-learning studies are described as showing strong predictive potential but numerical sensitivity/specificity are not detailed in this review.",
            "study_type": "review citing deep learning imaging studies (model development/validation on PET datasets)",
            "study_population": "Referenced usage on datasets such as ADNI and other PET cohorts; exact sample descriptions not provided in this review.",
            "controversies_or_limitations": "PET involves radionuclide exposure and cost; generalizability and robustness of deep learning models require careful validation and control for biases; the review stresses need for positive/bias controls and visualization techniques to validate deep learning findings.",
            "uuid": "e9982.7",
            "source_info": {
                "paper_title": "Artificial Intelligence for Alzheimer’s Disease Detection: Enhancing Biomarker Analysis and Diagnostic Precision †",
                "publication_date_yy_mm": "2024-11"
            }
        },
        {
            "name_short": "AI imaging models (CNNs)",
            "name_full": "Deep learning convolutional neural network models for AD detection (e.g., VGG, InceptionV3, ensemble CNNs)",
            "brief_description": "Deep learning architectures applied to MRI and PET imaging to classify AD, distinguish AD from healthy controls, and predict MCI-to-AD conversion, often using transfer learning and ensemble strategies.",
            "citation_title": "Artificial Intelligence for Alzheimer's Disease Detection: Enhancing Biomarker Analysis and Diagnostic Precision",
            "mention_or_use": "mention",
            "cause_type": "detection method / computational approach",
            "cause_description": "Not a causal mechanism; computational models (CNNs, transfer learning) process imaging and biomarker data to detect patterns indicative of AD.",
            "evidence_for_cause": "The review cites multiple studies: InceptionV3 trained on F-FDG PET (prospective); Mehmood et al. applied VGG on MRI achieving 'high accuracy' for AD vs controls; Choi et al. developed a CNN predicting cognitive decline in MCI patients with 84.2% accuracy for conversion; other studies combine GMM/CNN segmentation with XGBoost/SVM classification showing promising classification performance.",
            "evidence_against_cause": "The paper notes important limitations and necessary controls: DL models require large datasets, are sensitive to noise and bias, and results need validation (including use of bias control models and visualization techniques); it references at least one study where deep learning showed no morphological abnormalities in neutrophils, indicating null findings are possible and that model outputs must be validated.",
            "detection_method_type": "AI / machine learning / deep learning applied to imaging and biomarker data",
            "detection_method_description": "Convolutional neural networks (InceptionV3, VGG, custom CNNs), transfer learning, ensemble models, and hybrid pipelines combining segmentation (GMM + CNN) with classifiers (XGBoost, SVM) applied to MRI, FDG-PET, amyloid PET, and blood/CSF data.",
            "detection_performance": "Reported performance in cited studies is heterogeneous; the review explicitly reports a PET-based CNN (Choi et al.) with 84.2% accuracy predicting MCI→AD conversion; other studies are described as achieving 'high accuracy' but numerical sensitivity and specificity are not consistently reported in this review.",
            "study_type": "review of AI model development and validation studies (retrospective/prospective ML studies cited)",
            "study_population": "Models are trained and validated on public neuroimaging/biomarker datasets such as ADNI, NACC, OASIS, and various clinical cohorts referenced by the cited literature; exact sizes/demographics vary by study and are not fully enumerated in this review.",
            "controversies_or_limitations": "Major limitations highlighted include high-dimensional noisy data, need for large labeled datasets, potential bias and overfitting, lack of standardized reporting of sensitivity/specificity across studies, requirement for rigorous validation (positive/bias controls), computational complexity, and challenges integrating AI tools into clinical workflows.",
            "uuid": "e9982.8",
            "source_info": {
                "paper_title": "Artificial Intelligence for Alzheimer’s Disease Detection: Enhancing Biomarker Analysis and Diagnostic Precision †",
                "publication_date_yy_mm": "2024-11"
            }
        },
        {
            "name_short": "CSF automated assays + unsupervised ML",
            "name_full": "Automated CSF assay platforms combined with unsupervised Gaussian mixture models",
            "brief_description": "Automated biochemical platforms for CSF core biomarkers analyzed with unsupervised machine learning (Gaussian mixture models) to classify biochemical profiles across neurological disorders.",
            "citation_title": "Artificial Intelligence for Alzheimer's Disease Detection: Enhancing Biomarker Analysis and Diagnostic Precision",
            "mention_or_use": "mention",
            "cause_type": "detection method / analytical pipeline",
            "cause_description": "Not a causal factor; methodological approach combining automated CSF biomarker assays (Aβ, t-tau, p-tau) with unsupervised GMM clustering to profile and classify patients biochemically.",
            "evidence_for_cause": "The paper describes a referenced study comparing two large cohorts of patients using automated assays and unsupervised GMM to classify patients by CSF biomarker profiles, suggesting improved biochemical profiling and diagnostic protocols.",
            "evidence_against_cause": "No explicit counter-evidence described in the review; practical limitations (assay availability/cost, invasiveness) remain relevant.",
            "detection_method_type": "CSF biomarker assay + unsupervised ML",
            "detection_method_description": "Automated CSF biomarker platforms measuring Aβ, t-tau, p-tau, with unsupervised Gaussian mixture modeling to classify patients based on biomarker distributions.",
            "detection_performance": "The review summarizes that unsupervised ML can improve biochemical profiling but does not supply numeric performance metrics (sensitivity/specificity) for the clustering/classification outcomes in the referenced study.",
            "study_type": "review citing cohort biomarker/ML study (unsupervised learning applied to CSF assays)",
            "study_population": "Two large cohorts of patients with various neurological disorders are referenced (exact sizes/demographics not specified in this review).",
            "controversies_or_limitations": "Limitations include invasiveness of CSF sampling, costs, assay variability, and the need to validate clustering-derived classes against clinical outcomes; unsupervised outputs require careful interpretation for clinical use.",
            "uuid": "e9982.9",
            "source_info": {
                "paper_title": "Artificial Intelligence for Alzheimer’s Disease Detection: Enhancing Biomarker Analysis and Diagnostic Precision †",
                "publication_date_yy_mm": "2024-11"
            }
        }
    ],
    "potentially_relevant_new_papers": [
        {
            "paper_title": "A deep learning model to predict a diagnosis of Alzheimer disease by using 18F-FDG PET of the brain.",
            "rating": 2,
            "sanitized_title": "a_deep_learning_model_to_predict_a_diagnosis_of_alzheimer_disease_by_using_18ffdg_pet_of_the_brain"
        },
        {
            "paper_title": "Predicting cognitive decline with deep learning of brain metabolism and amyloid imaging.",
            "rating": 2,
            "sanitized_title": "predicting_cognitive_decline_with_deep_learning_of_brain_metabolism_and_amyloid_imaging"
        },
        {
            "paper_title": "Biomarkers for the Diagnosis of Alzheimer's Disease in Clinical Practice: The Role of CSF Biomarkers during the Evolution of Diagnostic Criteria.",
            "rating": 2,
            "sanitized_title": "biomarkers_for_the_diagnosis_of_alzheimers_disease_in_clinical_practice_the_role_of_csf_biomarkers_during_the_evolution_of_diagnostic_criteria"
        },
        {
            "paper_title": "Biomarkers for the Early Detection and Progression of Alzheimer's Disease.",
            "rating": 2,
            "sanitized_title": "biomarkers_for_the_early_detection_and_progression_of_alzheimers_disease"
        },
        {
            "paper_title": "A Survey of Deep Learning for Alzheimer's Disease.",
            "rating": 1,
            "sanitized_title": "a_survey_of_deep_learning_for_alzheimers_disease"
        },
        {
            "paper_title": "Machine Learning Driven Profiling of Cerebrospinal Fluid Core Biomarkers in Alzheimer's Disease and Other Neurological Disorders.",
            "rating": 2,
            "sanitized_title": "machine_learning_driven_profiling_of_cerebrospinal_fluid_core_biomarkers_in_alzheimers_disease_and_other_neurological_disorders"
        },
        {
            "paper_title": "Blood Transcript Biomarkers Selected by Machine Learning Algorithm Classify Neurodegenerative Diseases including Alzheimer's Disease.",
            "rating": 2,
            "sanitized_title": "blood_transcript_biomarkers_selected_by_machine_learning_algorithm_classify_neurodegenerative_diseases_including_alzheimers_disease"
        },
        {
            "paper_title": "Advancements in computer-assisted diagnosis of Alzheimer's disease: A comprehensive survey of neuroimaging methods and AI techniques for early detection.",
            "rating": 1,
            "sanitized_title": "advancements_in_computerassisted_diagnosis_of_alzheimers_disease_a_comprehensive_survey_of_neuroimaging_methods_and_ai_techniques_for_early_detection"
        }
    ],
    "cost": 0.018646,
    "model_str": "gpt-5-mini"
}</code></pre>
        </div>
        <div class="section">
            <h2>Paper</h2>
            <div class="paper-content"><p>Artificial Intelligence for Alzheimer's Disease Detection: Enhancing Biomarker Analysis and Diagnostic Precision †
14 November 2024</p>
<p>Richa Gupta richagupta@jamiahamdard.ac.in 
Department of Computer Science and Engineering
Jamia Hamdard110062New DelhiIndia</p>
<p>Zoya Iftekhar zoya.iftekhar23@gmail.com 0009-0008-9159-8293
Department of Computer Science and Engineering
Jamia Hamdard110062New DelhiIndia</p>
<p>Artificial Intelligence for Alzheimer's Disease Detection: Enhancing Biomarker Analysis and Diagnostic Precision †
14 November 20242A13D89D014CDA560D04F818FCC9A27510.3390/ecsoc-28-20206Gupta, R.Iftekhar, Z. Artificial Intelligence for Alzheimer's Disease Detection: Enhancing Biomarker Analysis and Diagnostic Alzheimer's disease detectionartificial intelligencebiomarker analysisneurodegenerative disordersearly diagnosisneuroimagingmachine learning
Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by cognitive decline and memory impairment.Early and accurate detection of AD is crucial for timely intervention and effective treatment.Biomarkers such as amyloid-beta and tau proteins, genetic markers like the APOE genotype, and neuroimaging findings are essential for AD diagnosis and prognosis, but their complex interactions require advanced analytical tools.AI has emerged as a transformative tool in healthcare, offering advanced computational techniques to analyze complex biomarker data with enhanced precision.This review paper explores the advancements in diagnosing Alzheimer's disease (AD) using artificial intelligence (AI) techniques.In the paper, we discuss the importance of diagnosing AD accurately and the potential benefits of using AI techniques for the early and accurate detection of AD.We emphasize the significance of AI in optimizing biomarker analysis for AD detection, discussing the challenges in their implementation and future implications.AI technologies can transform AD detection by significantly improving diagnostic imaging techniques, identifying key biomarkers, and standardizing the analysis of complex neuroimaging data.In this paper, we also highlight the critical role of AI in addressing challenges associated with integrating new technologies into clinical practice and providing effective solutions for consistent and reliable AD detection techniques.</p>
<p>Introduction 1.Overview of Alzheimer's Disease (AD)</p>
<p>AD is a progressive neurodegenerative disorder and the most prevalent cause of dementia accounting for an estimated 60-80% of cases [1,2].AD often initiates with a mild cognitive impairment (MCI) stage characterized primarily by memory loss, followed by a gradual decline that encompasses behavioral issues and reduced self-care.The disease develops very slowly, and the resulting changes are irreversible.Prodrome diagnosis of AD, especially in MCI state, is especially crucial so that one can take therapeutic measures and delay the disease progression.MCI is a transitional stage between normal cognitive aging and more serious conditions like dementia.MCI includes several types: amnestic MCI (aMCI), primarily affecting memory; early MCI (eMCI), characterized by subtle cognitive changes; late MCI (lMCI), involving more pronounced deficits; and non-amnestic MCI, which impacts other cognitive functions.Additionally, subjective cognitive decline (SMC) refers to self-reported cognitive concerns without measurable impairment [3].Understanding these distinctions is crucial for diagnosis and prognosis, informing treatment strategies [4].Pathological abnormalities, such as amyloid plaques, can form 10-20 years prior to cognitive dysfunction and significant nerve cell loss [5].They affect the central Chem.Proc.2024, 16, 25 2 of 7 nervous system (CNS) through the excessive accumulation of protein fragment β-amyloid and an abnormal form of the protein tau plaques [1].This accumulation is followed by neurodegeneration, which causes structural changes and a loss of functional connectivity and damage to other brain cells.Additionally, there are alterations in reactive processes, including neuroinflammation and changes in plasticity, which are associated with oxidative stress and mitochondrial dysfunction [1].Another brain change linked to Alzheimer's disease is atrophy, characterized by a reduction in brain volume due to neurodegeneration and other factors [2]. Figure 1 illustrates AD progression in brain.Detecting AD at its onset enables timely intervention with medications and lifestyle adjustments that may slow progression and enhance quality of life and prevent fatality.It also aids in planning for future care, differentiates AD from other cognitive disorders, and allows for access to support resources and clinical trials [3][4][5][6][7][8].</p>
<p>Chem.Proc.2024, 16, 25 2 nervous system (CNS) through the excessive accumulation of protein fragment β-am and an abnormal form of the protein tau plaques [1].This accumulation is followe neurodegeneration, which causes structural changes and a loss of functional connect and damage to other brain cells.Additionally, there are alterations in reactive proce including neuroinflammation and changes in plasticity, which are associated with o tive stress and mitochondrial dysfunction [1].Another brain change linked to Alzheim disease is atrophy, characterized by a reduction in brain volume due to neurodege tion and other factors [2].</p>
<p>Role of Biomarkers in AD</p>
<p>Biomarkers play a critical role in the diagnosis, prognosis, and management o [9,10].Biomarkers can be defined as "a characteristic that is objectively measured evaluated as an indicator of normal biological processes, pathogenic processes or p macological responses to a therapeutic intervention" [11].They provide measurable cators of biological processes, enabling early detection and monitoring of disease pro sion.The development of early and reliable diagnostic markers is essential for dete the disease sooner, enabling preventive actions to prevent further neuronal damage [</p>
<p>AI in Healthcare</p>
<p>AI has emerged as a transformative tool in healthcare, offering innovative comp tional techniques to analyze complex biomarker data with enhanced precision.I demonstrated a significant potential in enhancing the detection and diagnosis of A identifying intricate patterns in large datasets and analyzing large volumes of genetic aging, and clinical data generated during neurodegenerative disease research [11-13 techniques like deep learning and natural language processing have transfor healthcare, leveraging datasets such as ADNI, NACC, and OASIS.ADNI enables pr tive modeling in Alzheimer's disease through neuroimaging and biomarker data, w NACC and OASIS provide extensive clinical and imaging resources for studying ne degenerative diseases.These tools enhance diagnosis and personalized treatment st gies.AI can optimize biomarker analysis, enhance neuroimaging techniques, and pro more consistent and reliable diagnostic solutions [14,15].The rapid increase in comp tional power, along with advancements in AI, has opened up new possibilities for an ing complex medical data, such as neuroimaging scans and biomarker profiles [16].In review, we discuss the AI techniques that can be utilized to enhance biomarker ana and improve diagnostic precision with respect to AD.</p>
<p>Biomarkers in AD</p>
<p>Neuroimaging techniques, including imaging modalities like magnetic reson</p>
<p>Role of Biomarkers in AD</p>
<p>Biomarkers play a critical role in the diagnosis, prognosis, and management of AD [9,10].Biomarkers can be defined as "a characteristic that is objectively measured and evaluated as an indicator of normal biological processes, pathogenic processes or pharmacological responses to a therapeutic intervention" [11].They provide measurable indicators of biological processes, enabling early detection and monitoring of disease progression.The development of early and reliable diagnostic markers is essential for detecting the disease sooner, enabling preventive actions to prevent further neuronal damage [3-5].</p>
<p>AI in Healthcare</p>
<p>AI has emerged as a transformative tool in healthcare, offering innovative computational techniques to analyze complex biomarker data with enhanced precision.It has demonstrated a significant potential in enhancing the detection and diagnosis of AD by identifying intricate patterns in large datasets and analyzing large volumes of genetic, imaging, and clinical data generated during neurodegenerative disease research [11][12][13].AI techniques like deep learning and natural language processing have transformed healthcare, leveraging datasets such as ADNI, NACC, and OASIS.ADNI enables predictive modeling in Alzheimer's disease through neuroimaging and biomarker data, while NACC and OASIS provide extensive clinical and imaging resources for studying neurodegenerative diseases.These tools enhance diagnosis and personalized treatment strategies.AI can optimize biomarker analysis, enhance neuroimaging techniques, and provide more consistent and reliable diagnostic solutions [14,15].The rapid increase in computational power, along with advancements in AI, has opened up new possibilities for analyzing complex medical data, such as neuroimaging scans and biomarker profiles [16].In this review, we discuss the AI techniques that can be utilized to enhance biomarker analysis and improve diagnostic precision with respect to AD.</p>
<p>Biomarkers in AD</p>
<p>Neuroimaging techniques, including imaging modalities like magnetic resonance imaging (MRI) and positron emission tomography (PET) scans, play a crucial role in detecting structural brain changes and visualizing pathological features like amyloid-β plaques and tau tangles [1,3,5].These techniques help identify the characteristic patterns of brain atrophy and protein accumulation associated with AD [17,18].CSF analysis can also reveal biomarkers related to AD pathology, providing further evidence to support a diagnosis [19].Blood-based biomarkers are being developed to provide a less invasive diagnostic option [3,4].Genetic testing, such as for the APOE ε4 variant, can indicate an increased risk of AD but is not used in isolation for diagnostic purposes.A summary of traditional biomarkers is given in Table 1 [1,3,11,18].</p>
<p>Recent Advances in AI Techniques for Biomarker Analysis</p>
<p>Machine learning involves creating algorithms and statistical models that let computers learn from experience and become better at completing tasks.Deep learning can perform classification tasks on images, text, or sound by using large datasets and multilayered neural networks [20,21].DL models consist of multiple layers of neurons which are trained on large datasets of images to learn patterns and features that are useful for image analysis.DL models can automatically learn relevant features from the data [12,14].Transfer learning is another algorithm which is used in AD detection where a model developed for a specific task is adapted for a different but related task.Instead of training a new model, which requires substantial data and computational resources, transfer learning leverages the knowledge gained from a pre-trained model.Figure 2 illustrates the algorithms used for diagnosis of AD.</p>
<p>image analysis.DL models can automatically learn relevant features from the data [12,14].Transfer learning is another algorithm which is used in AD detection where a model developed for a specific task is adapted for a different but related task.Instead of training a new model, which requires substantial data and computational resources, transfer learning leverages the knowledge gained from a pre-trained model.Figure 2 illustrates the algorithms used for diagnosis of AD.</p>
<p>AI in Imaging Biomarkers</p>
<p>Magnetic resonance imaging (MRI) and positron emission tomography (PET) are two medical imaging techniques that are widely used for the early detection of AD [20].A review of neuroimaging approaches and AI methods for early detection has been covered in [14].In [20], prospective F-FDG PET brain scans have been employed to train a 48-layer deep convolutional neural network named InceptionV3.Mehmood et al. [21] employed MRI images with a pre-trained VGG convolutional neural network, achieving high accuracy in distinguishing AD patients from healthy controls.A computational method for diagnosing AD from brain MRI scans proposed in [22] is a combination of Gaussian mixture model (GMM) and a convolutional neural network (CNN) for tissue segmentation.It also employs extreme gradient boosting (XGBoost) with a support vector machine (SVM) for classifying Alzheimer's disease based on the segmented tissues.Popuri [23] proposed a novel biomarker using MRI-based features to measure neurodegeneration.Choi et al. [24] developed a CNN system that accurately predicts cognitive decline in MCI patients using PET images.The model achieved 84.2% accuracy in predicting MCI to AD conversion.</p>
<p>AI in Cerebrospinal Fluid(CSF) Biomarkers</p>
<p>CSF biomarkers are promising for Alzheimer's diagnosis but involve an invasive lumbar puncture, which can be uncomfortable and carries some risk.The test's cost and availability may also limit its use [25][26][27].Ref. [15] discusses the use of automated platforms for assessing core AD biomarkers in CSF.The study compares two large cohorts of patients with various neurological disorders and applies unsupervised Gaussian mixture models to classify patients based on their CSF biomarker profiles.The findings suggest that automated assays and unsupervised machine learning approaches can help in the biochemical profiling of neurological disorders and improve diagnostic protocols.Diagnostic guidelines include CSF levels of amyloid-beta, total tau protein, p-tau [28][29][30].</p>
<p>AI in Blood-Based Biomarkers</p>
<p>Brain-derived biomarkers are generally found in lower concentrations in blood compared to CSF primarily due to the blood-brain barrier, which restricts the free movement of substances between the central nervous system and the bloodstream.Advances have been made to enhance the analytical sensitivity of these methods [14].It has been discovered that combining blood bio-marker detection with imaging markers may help enhance the accuracy of AD diagnosis [25].Blood-based data are emerging as a promising noninvasive biomarker for Alzheimer's disease.Generated through omics techniques, these data are complex, high-dimensional, and voluminous, making manual analysis difficult.Ref. study [26] explores the use of AI to identify small sets of blood transcripts that can differentiate between healthy individuals and those with AD.The combination of DL models with imaging from blood samples to investigate AD has been suggested in [27], where the authors concluded that a robust deep learning pipeline, which incorporates positive and bias control models along with visualization techniques, is valuable for validating the results of deep learning models.</p>
<p>AI in Genetic Biomarkers</p>
<p>By integrating genetic data with other types of omics information, such as transcriptomics and proteomics, AI provides a comprehensive view of the biological pathways involved in AD, enabling the identification of novel genetic biomarkers associated with early disease onset [12].APOE ε4 is a key genetic biomarker for Alzheimer's disease (AD), with its risk association varying by genotype.Individuals with two ε4 alleles (ε4/ε4) have a significantly higher risk than those with one ε4 allele combined with an ε3 allele (ε4/ε3).Additionally, the presence of the ε2 allele (ε2/ε4 or ε2/ε3) appears to confer some protective effects against AD.Understanding these combinations is crucial for risk assessment and research.By processing genetic data in real time, AI improves the detection of early biomarkers and supports personalized treatment strategies, thereby advancing the early diagnosis and management of AD [6].This integration of AI and genetic biomarkers enhances the accuracy of early diagnosis and supports the development of personalized treatment strategies by identifying individuals at higher risk [6,14].</p>
<p>Enhancing Diagnostic Precision and Advances in AD Monitoring Using AI</p>
<p>The data produced by non-invasive methods are highly complex due to noise, large volume, high dimensionality, and variability [12].Analyzing thousands of MRI or PET images presents a level of computational complexity that simple methods cannot handle [14].Blood screening data include omics measurements with an exceptionally high number of samples and features.This complexity makes it challenging to analyze and interpret using traditional statistical methods.Table 2 gives a summary of various AI techniques that can be used for biomarker analysis.AI techniques can help to identify patterns in data and generate predictive models that can assist in the early and accurate detection of AD.</p>
<p>Conclusions</p>
<p>The advent of artificial intelligence (AI) and deep learning (DL) is set to revolutionize Alzheimer's disease (AD) detection by enhancing biomarker analysis and diagnostic precision.Early and accurate diagnosis of AD is essential for improving patient quality of life through timely preventative measures.To achieve this, there is a growing need to identify and utilize AI-based biomarkers that can detect early cognitive deviations indicative of AD.As non-invasive technologies advance and more data are generated, the role of AI will become increasingly pivotal.AI technologies have demonstrated a significant potential in enhancing the detection and diagnosis of AD by identifying intricate patterns in large datasets that may elude traditional analysis methods.By combining these computational tools with non-invasive, as well invasive, biomarker approaches, we can expect significant improvements in the early detection and diagnosis of AD.</p>
<p>Figure 1 illustrates
1
AD progression in brain.Detecting AD onset enables timely intervention with medications and lifestyle adjustments that slow progression and enhance quality of life and prevent fatality.It also aids in plan for future care, differentiates AD from other cognitive disorders, and allows for acce support resources and clinical trials [3-8].</p>
<p>Figure 1 .
1
Figure 1.Illustration of AD progression, including the healthy brain, mild AD, and severe AD</p>
<p>Figure 1 .
1
Figure 1.Illustration of AD progression, including the healthy brain, mild AD, and severe AD.</p>
<p>Figure 2 .
2
Figure 2. Different types of algorithms used for diagnosing Alzheimer's disease [14].Figure 2. Different types of algorithms used for diagnosing Alzheimer's disease [14].</p>
<p>Figure 2 .
2
Figure 2. Different types of algorithms used for diagnosing Alzheimer's disease [14].Figure 2. Different types of algorithms used for diagnosing Alzheimer's disease [14].</p>
<p>Table 1 .
1
[1,ma11,18]various traditional biomarkers that are used for AD detection.Created by author and reference taken form[1,3,11,18].
CategoryBiomarkerDescriptionKey FeatureMRIGrey matter volumeMeasures the volume of grey matter in the brain, indicating atrophyReflects structural changes in neurodegenerationVisualizes amyloid-betaPETAmyloid-beta depositionplaques and tau tangles usingDirect detection of pathologyradiotracersAmyloid-betaIndicates amyloid plaqueMeasured using ELISA or(Aβ42)deposition in the brainmass spectrometryCerebrospinal fluid (CSF)Total tauMeasures levels of total tauReflects neuronal damage andbiomarkers(t-tau)protein in CSFdegenerationPhosphorylated tau (p-tau)Measures levels of phosphorylated tau protein in CSFIndicates neurofibrillary degenerationAmyloid-beta (Aβ42 and Aβ40)Measures levels of amyloid-beta in blood plasmaReflects amyloid plaque depositionBlood-based biomarkersTau proteins (t-tau and p-tau)Measures levels of tau proteins in blood plasmaIndicates tau pathologyNeurofilament light chain (NFL)Measures levels of NFL in blood plasmaReflects neurodegenerationGenetic biomarkersAPOE genotype (APOE ε4)Identifies presence of APOE ε4 allele, associated with increased genetic risk for ADDNA sequencing or genotyping assays, including PCR-based methods are used</p>
<p>Table 2 .
2
Summary of various AI techniques that can be used for biomarker analysis.
CategoryBiomarkerTechniqueReferencesVGG (CNN);MRIGrey matter volumeSegmentation: GMM and CNN models; Classification: XGBoost and SVM;[14,21-23]Novel biomarker based on MRIPETAmyloid-beta deposition(InceptionV3) CNN; Imaging analysis using CNN Ensemble model;[14,20,24]Gaussian mixture models;Amyloid-beta (Aβ42)Automated assays;[15]Unsupervised learningCerebrospinal fluid (CSF) biomarkersTotal tau (t-tau)Gaussian mixture models; Unsupervised learning Automated assays;[15]Gaussian mixture models;Phosphorylated tau (p-tau)Automated assays;[15]Unsupervised learningAmyloid-beta (Aβ42 and Aβ40)CNN on imaging blood samples VGG-16 and Inceptionv3[14,25-27]Blood-based biomarkersTau proteins (t-tau and p-tau)CNN on imaging blood samples VGG-16 and Inceptionv3[14,25-27]Neurofilament light chain (NFL)Regression models; Ensemble methods Neural networks;[14,25-27]Genetic biomarkersAPOE genotype (APOE ε4)CNN; Supervised learning methods[6,12,14]
; Available online: https://sciforum.net/event/ecsoc-28.Data Availability Statement: Data are contained within the article.Conflicts of Interest:The authors declare no conflict of interest.This research received no external funding.Institutional Review Board Statement: Not applicable.Author Contributions: Conceptualization, R.G. and Z.I.; methodology, Z.I.; resources, Z.I.; writing-
Biomarkers for Alzheimer's Disease Early Diagnosis. E Ausó, V Gómez-Vicente, G Esquiva, 10.3390/jpm10030114J. Pers. Med. 102020</p>
<p>Alzheimer's Disease Facts and Figures. Alzheimers Dement. 2024. 1 January 2020Alzheimer's Association</p>
<p>Biomarkers for the Diagnosis of Alzheimer's Disease in Clinical Practice: The Role of CSF Biomarkers during the Evolution of Diagnostic Criteria. M Dulewicz, A Kulczy'nska-Przybik, P Mroczko, J Kornhuber, P Lewczuk, B Mroczko, 10.3390/ijms23158598Int. J. Mol. Sci. 232022</p>
<p>Recent Advancements in Electrochemical Biosensors for Alzheimer's Disease Biomarkers Detection. E Mikuła, 10.2174/0929867327666201111141341Curr. Med. Chem. 282021</p>
<p>Biomarkers for the Early Detection and Progression of Alzheimer's Disease. S E Counts, M D Ikonomovic, N Mercado, I E Vega, E J Mufson, 10.1007/s13311-016-0481-z201714</p>
<p>Integrated multi-omics analysis of Alzheimer's disease shows molecular signatures associated with disease progression and potential therapeutic targets. P Kodam, R Sai Swaroop, S S Pradhan, V Sivaramakrishnan, R Vadrevu, 10.1038/s41598-023-30892-6Sci. Rep. 132023</p>
<p>Alzheimer's disease Advax(CpG)-adjuvanted Multi-TEP-based dual and single vaccines induce high-titer antibodies against various forms of tau and Aβ pathological molecules. H Davtyan, K Zagorski, H Rajapaksha, A Hovakimyan, A Davtyan, I Petrushina, K Kazarian, D H Cribbs, N Petrovsky, M G Agadjanyan, 10.1038/srep28912Sci. Rep. 2016, 6, 28912</p>
<p>Medical image analysis based on deep learning approach. M Puttagunta, S Ravi, Multimed. Tools Appl. 802021</p>
<p>Body fluid biomarkers in Alzheimer's disease. H Lu, X.-C Zhu, T Jiang, J.-T Yu, L Tan, Ann. Transl. Med. 2015, 3, 70</p>
<p>Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework. 10.1067/mcp.2001.113989Biomarkers Definitions Working Group. 692001Clin. Pharmacol. Ther.</p>
<p>Machine Learning Driven Profiling of Cerebrospinal Fluid Core Biomarkers in Alzheimer's Disease and Other Neurological Disorders. B Giovanni, I Antonio, C Davide, M Emanuela, P P Federico, G Lorenzo, P Silvia, P Maya, T Fabrizio, G Giorgio, 10.3389/fnins.2021.647783Front. Neurosci. 152021</p>
<p>A Survey of Deep Learning for Alzheimer's Disease. Q Zhou, J Wang, X Yu, S Wang, Y Zhang, 10.3390/make5020035Mach. Learn. Knowl. Extr. 52023</p>
<p>Applications of Artificial Intelligence to Diagnosis of Neurodegenerative Diseases. T Feng, Stud. Health Technol. Inform. 3082023</p>
<p>. Chem. Proc. 2024</p>
<p>Advancements in computer-assisted diagnosis of Alzheimer's disease: A comprehensive survey of neuroimaging methods and AI techniques for early detection. K Shanmugavadivel, V E Sathishkumar, J Cho, M Subramanian, 10.1016/j.arr.2023.102072Ageing Res. Rev. 912023. 102072</p>
<p>The Role of Biomarkers in Alzheimer's Disease Drug Development. J Cummings, Adv. Exp. Med. Biol. 2019, 1118</p>
<p>Deep Learning-Based Diagnosis of Alzheimer's Disease. T J Saleem, S R Zahra, F Wu, A Alwakeel, M Alwakeel, F Jeribi, M Hijji, 10.3390/jpm12050815J. Pers. Med. 122022</p>
<p>Alzheimer's disease CSF biomarkers: Clinical indications and rational use. E Niemantsverdriet, S Valckx, M Bjerke, S Engelborghs, 10.1007/s13760-017-0816-5Acta Neurol. Belg. 1172017</p>
<p>. M H Janeiro, C G Ardanaz, N Sola-Sevilla, J Dong, M Cortés-Erice, M Solas, E Puerta, M J Ramírez, 10.1515/almed-2020-0090Biomarkers in Alzheimer's disease. Adv. Lab. Med. 22021</p>
<p>Applications of artificial intelligence to aid early detection of dementia: A scoping review on current capabilities and future directions. R Li, X Wang, K Lawler, S Garg, Q Bai, J Alty, 10.1016/j.jbi.2022.104030J. Biomed. Inform. 2172022. 104030</p>
<p>A deep learning model to predict a diagnosis of Alzheimer disease by using 18F-FDG PET of the brain. Y Ding, J H Sohn, M G Kawczynski, H Trivedi, R Harnish, N W Jenkins, D Lituiev, T P Copeland, M S Aboian, C Mari Aparici, 10.1148/radiol.2018180958Radiology. 2902019</p>
<p>A transfer learning approach for early diagnosis of Alzheimer's disease on MRI images. A Mehmood, S Yang, Z Feng, M Wang, A S Ahmad, R Khan, M Maqsood, M Yaqub, 10.1016/j.neuroscience.2021.01.002Neuroscience. 4602021</p>
<p>Alzheimer's diagnosis using deep learning in segmenting and classifying 3D brain MR images. T A Tuan, T B Pham, J Y Kim, J M R Tavares, 10.1080/00207454.2020.1835900Int. J. Neurosci. 1322022</p>
<p>Alzheimer's Disease Neuroimaging Initiative. Development and validation of a novel dementia of Alzheimer's type (DAT) score based on metabolism FDG-PET imaging. K Popuri, R Balachandar, K Alpert, D Lu, M Bhalla, I R Mackenzie, R G Hsiung, L Wang, M F Beg, 10.1016/j.nicl.2018.03.007NeuroImage Clin. 182018</p>
<p>Alzheimer's Disease Neuroimaging Initiative. Predicting cognitive decline with deep learning of brain metabolism and amyloid imaging. H Choi, K H Jin, 10.1016/j.bbr.2018.02.017Behav. Brain Res. 3442018</p>
<p>Current trends in blood biomarker detection and imaging for Alzheimer's disease. S Hu, C Yang, H Luo, 10.1016/j.bios.2022.114278Biosens. Bioelectron. 2102022. 114278</p>
<p>Blood Transcript Biomarkers Selected by Machine Learning Algorithm Classify Neurodegenerative Diseases including Alzheimer's Disease. C J Huseby, E Delvaux, D L Brokaw, P D Coleman, 10.3390/biom12111592Biomolecules. 122022. 1592</p>
<p>Deep learning shows no morphological abnormalities in neutrophils in Alzheimer's disease. Alzheimer's Dement. F Chabrun, X Dieu, N Doudeau, J Gautier, D Luque-Paz, F Geneviève, M Ferré, D Mirebeau-Prunier, C Annweiler, P Reynier, 10.1002/dad2.12146Diagn. Assess. Dis. Monit. 132021. e12146</p>
<p>Predicting Alzheimer's disease by hierarchical graph convolution from positron emission tomography imaging. J Guo, W Qiu, X Li, X Zhao, N Guo, Q Li, 10.1109/BigData47090.2019.9005971Proceedings of the 2019 IEEE International Conference on Big Data (Big Data). the 2019 IEEE International Conference on Big Data (Big Data)Los Angeles, CA, USA9-12 December 2019</p>
<p>Revolutionizing the Early Detection of Alzheimer's Disease through Non-Invasive Biomarkers: The Role of Artificial Intelligence and Deep Learning. A G Vrahatis, K Skolariki, M G Krokidis, K Lazaros, T P Exarchos, P Vlamos, 10.3390/s23094184Sensors. 232023</p>
<p>Magnetic resonance imaging and positron emission tomography in the diagnosis of neurodegenerative dementias. A Del Sol, S Malaspina, A M Biasina, 10.11138/FNeur/2016.31.4.205Funct. Neurol. 312016</p>
<p>Disclaimer/Publisher's Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods. instructions or products referred to in the content</p>            </div>
        </div>

    </div>
</body>
</html>